Lactoferrin
15 benefits mapped to clinical evidence across supplements.
Dose per serving from products
124 products in our catalogue print how much Lactoferrin a serving holds.
Most common: 50 mg to 100 mg, 23% of 124 products.
| Dose per serving | Products |
|---|---|
| 5 mg or less | 2 |
| 5 mg to 10 mg | 10 |
| 10 mg to 25 mg | 11 |
| 25 mg to 50 mg | 22 |
| 50 mg to 100 mg | 28 |
| 100 mg to 250 mg | 18 |
| 250 mg to 500 mg | 19 |
| 500 mg to 1 g | 9 |
| over 1 g | 5 |
Dose per serving from research
58 study groups in 42 studies say how much Lactoferrin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 50 mg to 100 mg, 28% of 58 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg or less | 3 |
| 50 mg to 100 mg | 16 |
| 100 mg to 250 mg | 14 |
| 250 mg to 500 mg | 7 |
| 500 mg to 1 g | 6 |
| 1 g to 2.5 g | 3 |
| 2.5 g to 5 g | 6 |
| 5 g to 10 g | 1 |
| over 10 g | 2 |
Commonly used together
16 of 64 study groups took Lactoferrin with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Probiotics | 3 |
Benefit Evidence
Research sources
Antimicrobial (34)
- Effects of Lactoferrin on Prevention of Acute Gastrointestinal Symptoms in Winter: A Randomized, Double-Blinded, Placebo-Controlled Trial for Staff of Kindergartens and Nursery Schools in Japan
PubMed ID: 33371454
Childcare workers taking LF experienced fewer and shorter GI infection episodes (practical antimicrobial/prophylactic effect).
- Supporting respiratory epithelia and lowering inflammation to effectively treat common cold symptoms: A randomized controlled trial
PubMed ID: 39602479
Topical mucosal spray containing LF (with lysozyme/aloe) significantly reduced cold symptoms and sore throat (clinical antimicrobial/antiviral benefit plausible).
- Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial
PubMed ID: 34102559
Bovine LF in formula reduced diarrheal and respiratory infections and raised fecal antimicrobial peptides (direct enhancement of mucosal antimicrobial defenses).
- Oropharyngeal colostrum administration in extremely premature infants: an RCT
PubMed ID: 25624376
Oropharyngeal colostrum in extremely preterm infants markedly reduced clinical sepsis and raised lactoferrin/sIgA — strong antimicrobial/mucosal immunity signal.
- Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study
PubMed ID: 16369731
Randomized placebo‑controlled human trial: 200 mg bLF twice daily significantly reduced H. pylori colonization vs placebo — strong direct antimicrobial evidence in gut.
- Effects of lactoferrin and lactoperoxidase-containing food on the oral microbiota of older individuals
PubMed ID: 28881387
Oral tablets with LF+lactoperoxidase lowered gram‑negative oral bacteria and improved malodor — direct antimicrobial action in the oral cavity.
- The effect of enzyme and protein containing toothpaste on gingival condition: a randomised controlled study
PubMed ID: 41184910
Toothpaste with lactoferrin and enzymes reduced plaque and gingival inflammation, consistent with antimicrobial effects in the oral cavity.
- Iron metabolism in infants: influence of bovine lactoferrin from iron-fortified formula
PubMed ID: 25592008
Infant formula with lactoferrin raised iron indices and reduced anemia/iron deficiency; lactoferrin also associated with lower infection rates in other infant studies.
- Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial
PubMed ID: 26602290
Lactoferrin‑fortified formula reduced diarrhea and respiratory symptom incidence in infants, consistent with antimicrobial/anti‑infective benefit.
- Preventing Sepsis in Preterm Infants with Bovine Lactoferrin: A Randomized Trial Exploring Immune and Antioxidant Effects
PubMed ID: 41097231
Enteral bLf reduced late‑onset sepsis incidence in very preterm/VLBW infants — strong clinical antimicrobial/protective signal.
- Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study
PubMed ID: 10948819
Oral bovine lactoferrin trial in tinea pedis showed symptomatic improvement (antimicrobial-related clinical effect though no mycological cure).
- Use of bovine lactoferrin for Helicobacter pylori eradication
PubMed ID: 14620619
Randomized trial: adding bovine lactoferrin to triple therapy markedly improved H. pylori eradication rates (strong human evidence of antimicrobial benefit adjunctive to therapy).
- Use of lactoferrin for Helicobacter pylori eradication. Preliminary results
PubMed ID: 12702979
Preliminary randomized results showed lactoferrin added to triple therapy gave much higher H. pylori cure rates (human clinical data).
- Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study
PubMed ID: 16611285
Large multicenter RCT: bovine lactoferrin added to triple therapy boosted eradication from ~77% to ~90% without more side effects (robust evidence).
- Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics
PubMed ID: 17313499
Adding bovine lactoferrin plus probiotics to H. pylori therapy increased cure rates and reduced side effects (human RCT supportive of antimicrobial adjunct effect).
- Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin
PubMed ID: 17914966
In HCV patients lactoferrin reduced viral RNA and improved SVR in responders (antiviral signal but subgroup-dependent).
- Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection
PubMed ID: 17392649
Second-line H. pylori therapy with added lactoferrin modestly reduced side effects and produced a small (non-significant) increase in cure rates.
- Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children
PubMed ID: 18462105
Daily bovine lactoferrin reduced Giardia colonization and duration in toddlers — direct antiparasitic/antimicrobial effect though not on overall diarrhea incidence.
- Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial
PubMed ID: 19809023
Large RCT in VLBW infants: oral bovine lactoferrin (± probiotic) produced a large, statistically significant reduction in late‑onset sepsis — strong antimicrobial/protective evidence.
- Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial
PubMed ID: 22184648
Secondary analysis from the same large trial: substantial reductions in invasive fungal infections and progression from colonization — strong antimicrobial support.
- The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study
PubMed ID: 23642947
Bovine lactoferrin/whey Ig preparation significantly reduced common cold incidence and symptom counts in susceptible adults — consistent with antimicrobial/antiviral activity of the product.
- Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial
PubMed ID: 24709463
Large VLBW RCT showed reduced NEC and death-or-NEC (especially with probiotic), consistent with antimicrobial/anti-infective benefits of BLF ± probiotic.
- Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells
PubMed ID: 24839144
Smaller RCT with significant reduction in nosocomial sepsis episodes and immunologic changes consistent with enhanced host defense.
- Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g
PubMed ID: 25973934
Peruvian neonatal RCT showed fewer late-onset sepsis episodes with LF supplementation (underpowered but clinically meaningful reductions).
- Efficacy of Bovine Lactoferrin Supplementation in Preventing Late-onset Sepsis in low Birth Weight Neonates: A Randomized Placebo-Controlled Clinical Trial
PubMed ID: 26224129
Randomized trial found markedly fewer culture-proven late-onset sepsis and sepsis-attributable deaths with BLF — strong infection-prevention signal.
- Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women
PubMed ID: 26118476
Observational analysis: higher genital soluble immune mediators including lactoferrin predicted increased antimicrobial (E. coli‑inhibitory) activity in cervicovaginal samples — supports LF's antimicrobial correlates.
- Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants
PubMed ID: 27260839
Talactoferrin reduced hospital-acquired infections and Gram‑positive bacteremia in VLBW infants (randomized trial) — supports anti-infective activity.
- Effects of lactoferrin and lactoperoxidase-containing food on the oral hygiene status of older individuals: A randomized, double blinded, placebo-controlled clinical trial
PubMed ID: 27150460
Lozenges with LF+lactoperoxidase lowered oral bacterial loads and periodontal pathogens in older adults — local antimicrobial effect.
- A randomized, double-blind, crossover, placebo-controlled clinical trial to assess effects of the single ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose oxidase on oral malodor
PubMed ID: 27001471
Single LF-containing lozenge acutely lowered hydrogen sulfide and total volatile sulfur compounds (oral antimicrobial/antimalodor effect).
- Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial
PubMed ID: 30525953
Adjunct LF+probiotic with antibiotics improved Nugent scores and reduced BV recurrence — clinical antimicrobial/microbiome benefit in the vagina.
- Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500 g: a pooled analysis of individual patient data from two randomized controlled trials
PubMed ID: 32931708
Individual-patient pooled analysis in very low birthweight infants found LF reduced late-onset sepsis in infants with little/no human milk (subgroup antimicrobial benefit).
- Efficacy of Lactoferrin with Standard Triple Therapy or Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial
PubMed ID: 34609303
Randomized controlled trial: adding bovine LF to standard H. pylori therapy significantly increased eradication rates (strong adjunct antimicrobial evidence).
- Evaluation of Bovine Lactoferrin for Prevention of Late-Onset Sepsis in Low-Birth-Weight Infants: A Double-Blind Randomized Controlled Trial
PubMed ID: 40507041
Large low‑birth‑weight infant trial showed a dose‑specific reduction in culture‑proven late‑onset sepsis at 150 mg bLF (but inconsistent across doses) — moderate antimicrobial signal.
- Efficacy of lactoferrin in preventing recurrent urinary tract infections in pregnant Egyptian women: a randomized controlled trial
PubMed ID: 40264102
Large randomized trial in pregnant women with prior recurrent UTI found daily LF dramatically reduced asymptomatic bacteriuria and symptomatic cystitis — strong, direct antimicrobial/anti‑infective evidence.
Immune support (22)
- Supporting respiratory epithelia and lowering inflammation to effectively treat common cold symptoms: A randomized controlled trial
PubMed ID: 39602479
Topical LF‑containing mucosal product reduced cold symptom severity rapidly (clinical protection against respiratory pathogens).
- Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial
PubMed ID: 34102559
Bovine LF reduced diarrhea and respiratory infections and increased fecal antimicrobial peptides/immune markers (direct enhancement of mucosal immunity).
- Oropharyngeal colostrum administration in extremely premature infants: an RCT
PubMed ID: 25624376
Oropharyngeal colostrum markedly increased urinary/salivary sIgA and LF and greatly reduced clinical sepsis in extremely preterm infants — strong evidence for immune strengthening in that population.
- Iron metabolism in infants: influence of bovine lactoferrin from iron-fortified formula
PubMed ID: 25592008
Infant formula with lactoferrin reduced anemia and infection risk markers; supports immune benefit in infants.
- Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial
PubMed ID: 26602290
Reduced respiratory infections in infants fed lactoferrin‑fortified formula implies immune‑protective effects.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
In IBD children, lactoferrin raised Hb, reduced IL‑6/hepcidin and had fewer side effects than ferrous sulfate, indicating improved host status and immune‑relevant inflammation control.
- Preventing Sepsis in Preterm Infants with Bovine Lactoferrin: A Randomized Trial Exploring Immune and Antioxidant Effects
PubMed ID: 41097231
bLf supplementation lowered late‑onset sepsis in VLBW infants — strong evidence for immune/protective benefit in that population.
- Lactoferrin regulates the immune responses in post-surgical patients
PubMed ID: 11726036
Oral lactoferrin given before thyroid surgery increased lymphocyte proliferation and LPS‑induced TNF‑alpha/IL‑6 production versus placebo (direct immunomodulatory human data).
- Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial
PubMed ID: 19809023
Large RCT demonstrated a marked reduction in late‑onset sepsis in VLBW infants receiving bovine lactoferrin, indicating meaningful enhancement of infection resistance.
- Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial
PubMed ID: 22184648
Marked reductions in invasive fungal infections and colonization‑to‑infection progression in the same VLBW cohort — strong immune/protective signal.
- A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis
PubMed ID: 23425819
Enteral talactoferrin in severe sepsis reduced mortality (phase II) — consistent with immune‑modulatory benefit in severe infection.
- The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study
PubMed ID: 23642947
Trial of bovine lactoferrin/whey Ig preparation substantially reduced common cold incidence in susceptible adults — supportive of enhanced host defense.
- Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial
PubMed ID: 24709463
Large RCT in VLBW infants found reductions in NEC and death-or-NEC (notably with added probiotic), consistent with a clinically important immune/protective effect of BLF.
- Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells
PubMed ID: 24839144
Smaller double-blind RCT showed significant reduction in nosocomial sepsis and increased regulatory-T responses with LF, supporting immunomodulatory benefit.
- Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g
PubMed ID: 25973934
Peruvian RCT suggested fewer late-onset sepsis episodes with LF supplementation (effects stronger but underpowered in lowest birth-weight subgroup).
- Efficacy of Bovine Lactoferrin Supplementation in Preventing Late-onset Sepsis in low Birth Weight Neonates: A Randomized Placebo-Controlled Clinical Trial
PubMed ID: 26224129
Randomized trial in low‑birth‑weight neonates produced fewer culture-proven LOS and eliminated sepsis-attributable deaths in LF arm — strong evidence of immune protection in this population.
- Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants
PubMed ID: 27260839
Talactoferrin decreased hospital-acquired infections in VLBW infants, consistent with immune-protective effects.
- Exposure to Gastric Acid Inhibitors Increases the Risk of Infection in Preterm Very Low Birth Weight Infants but Concomitant Administration of Lactoferrin Counteracts This Effect
PubMed ID: 29198543
Secondary analysis: BLF blunted increased infection risk from acid-suppressing drugs in VLBW infants, indicating protective immune effects in a high-risk context.
- Bovine Lactoferrin Enhances TLR7-Mediated Responses in Plasmacytoid Dendritic Cells in Elderly Women: Results From a Nutritional Intervention Study With Bovine Lactoferrin, GOS and Vitamin D
PubMed ID: 30515164
bLF increased pDC IL-6 and tended to raise IFN-α production in elderly women—direct evidence of immune cell activation by LF.
- Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500 g: a pooled analysis of individual patient data from two randomized controlled trials
PubMed ID: 32931708
Pooled neonatal data indicated LF reduced late-onset sepsis in infants lacking human milk (demonstrable protective immune effect in subgroup).
- Evaluation of Bovine Lactoferrin for Prevention of Late-Onset Sepsis in Low-Birth-Weight Infants: A Double-Blind Randomized Controlled Trial
PubMed ID: 40507041
Signal for reduced culture‑proven LOS at a specific dose in low‑birth‑weight infants suggests immune benefit in neonates, though overall trial results were mixed.
- Efficacy of lactoferrin in preventing recurrent urinary tract infections in pregnant Egyptian women: a randomized controlled trial
PubMed ID: 40264102
Marked reduction in ASB and symptomatic UTI with daily LF in pregnant women indicates a robust infection‑prevention/immunity‑related effect.
Wellbeing (19)
- Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy: a randomized clinical trial
PubMed ID: 26037728
Improved hemoglobin and tolerability in pregnancy with lactoferrin supports general maternal health/wellness.
- Effects of Lactoferrin on Prevention of Acute Gastrointestinal Symptoms in Winter: A Randomized, Double-Blinded, Placebo-Controlled Trial for Staff of Kindergartens and Nursery Schools in Japan
PubMed ID: 33371454
Fewer and shorter GI illness symptom days in childcare staff suggests improved day-to-day wellness.
- Improved Neurodevelopmental Outcomes Associated with Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula: A Randomized, Controlled Trial
PubMed ID: 31668885
Term infants fed MFGM+LF formula had better neurodevelopment scores and fewer infections — meaningful overall health benefit (multi-component product).
- Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 30829679
Reduced hospitalizations and acute malnutrition in at-risk toddlers receiving LF+lysozyme indicates important overall health improvements.
- Exposure to Gastric Acid Inhibitors Increases the Risk of Infection in Preterm Very Low Birth Weight Infants but Concomitant Administration of Lactoferrin Counteracts This Effect
PubMed ID: 29198543
Secondary analysis showed BLF supplementation largely offset infection risk associated with acid-suppressing drugs in VLBW infants — relevant to overall clinical outcomes.
- Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells
PubMed ID: 24839144
Reduced nosocomial sepsis and immunomodulatory changes (increased Tregs) in preterm infants suggest broader wellness benefits.
- Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial
PubMed ID: 24709463
Large multicenter RCT in VLBW infants showing reduced NEC and death-or-NEC (with probiotic) — major clinical benefit that contributes to overall health/wellness.
- The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study
PubMed ID: 23642947
Randomized trial of an Lf/Ig product sharply reduced common cold incidence and symptom burden in susceptible adults — meaningful wellness benefit.
- A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis
PubMed ID: 23425819
Talactoferrin reduced mortality in severe sepsis (phase II), indicating important acute‑illness wellness effects pending confirmation.
- Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial
PubMed ID: 22184648
Same large trial showed marked reductions in invasive fungal infections and progression from colonization — substantial overall health benefit in VLBW infants.
- Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial
PubMed ID: 19809023
Large multicenter RCT in VLBW infants showed a robust reduction in late‑onset sepsis with bovine lactoferrin, a major determinant of neonatal wellbeing.
- Preventing Sepsis in Preterm Infants with Bovine Lactoferrin: A Randomized Trial Exploring Immune and Antioxidant Effects
PubMed ID: 41097231
Reduced sepsis and preserved antioxidant capacity in VLBW infants indicate a meaningful clinical benefit to overall health in that population.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
Broad benefits in pediatric IBD (better Hb, lower inflammation, fewer GI side effects) support overall wellness.
- Effects of a Novel High-Quality Protein Infant Formula on Energetic Efficiency and Tolerance: A Randomized Trial
PubMed ID: 35666855
Infant formula containing lactoferrin supported normal growth with less intake and higher energetic efficiency, indicating wellness benefits in infants.
- The Preventive Effect of Lactoferrin-Containing Yogurt on Gastroenteritis in Nursery School Children-Intervention Study for 15 Weeks
PubMed ID: 32272777
Regular LF yogurt intake associated with fewer sick days and absences in nursery children (population-level wellness effect).
- Lactoferrin: A Promising New Player in Treatment of Iron Deficiency Anemia in Patients on Regular Hemodialysis: A Randomized Controlled Trial
PubMed ID: 38231718
In hemodialysis patients oral bovine lactoferrin markedly improved hepcidin, hemoglobin and iron indices vs oral iron—clinically meaningful systemic benefit.
- Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine
PubMed ID: 24867408
Long-term oral bLF raised serum LF and polyp-associated immune cells and inhibited polyp growth in a subgroup — positive systemic/long-term health signal.
- Oropharyngeal colostrum administration in extremely premature infants: an RCT
PubMed ID: 25624376
Oropharyngeal colostrum markedly raised mucosal immune markers and greatly reduced clinical sepsis in extremely preterm infants — strong overall wellness implication in that population.
- A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults
PubMed ID: 39465888
Randomized human study shows oral recombinant LF is safe and non‑immunogenic (supports safety/wellness).
Gut health (21)
- Lactobacilli vaginal colonisation after oral consumption of Respecta(®) complex: a randomised controlled pilot study
PubMed ID: 25855055
Small RCT: oral probiotic complex containing bovine LF increased vaginal detection of consumed Lactobacillus strains — LF included in product and part of microbiome-targeted intervention.
- Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants
PubMed ID: 27260839
Reduced hospital-acquired infections in VLBW infants and mechanistic relevance to gut-derived sepsis; supports gut-health benefit.
- Antibiotic treatment to prevent postextraction complications: a monocentric, randomized clinical trial. Preliminary outcomes
PubMed ID: 28569454
Probiotic product containing LF prevented antibiotic-associated GI side effects — suggests microbiome protective effect in combination product.
- Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial
PubMed ID: 30525953
Adjunct LF+probiotic therapy improved Nugent scores and reduced BV recurrence, demonstrating LF's role in restoring/maintaining a healthy mucosal microbiome.
- Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 30829679
Malawian toddler RCT of LF+lysozyme improved gut-barrier biomarker and markedly reduced hospitalization/acute malnutrition (strong gut-health evidence).
- Early Effect of Supplemented Infant Formulae on Intestinal Biomarkers and Microbiota: A Randomized Clinical Trial
PubMed ID: 32443684
Infant formula containing LF+probiotic+prebiotic produced fecal markers and microbiota closer to breastfed reference (multi-component result with notable gut effects).
- Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial
PubMed ID: 39565449
Randomized pilot in preterm infants: oral bLF shortened time to full feeds and lowered serum zonulin (intestinal permeability marker) — strong gut‑health evidence in this population.
- Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans
PubMed ID: 23674271
Blackcurrant product containing LF increased lactobacilli/bifidobacteria and decreased harmful species and β‑glucuronidase activity (microbiome shift shown).
- Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial
PubMed ID: 34102559
Bovine LF in weaned infants reduced diarrhea, respiratory infections and increased fecal antimicrobial peptides and sIgA (direct gut mucosal benefits).
- Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study
PubMed ID: 16369731
Oral bLF suppressed H. pylori colonization (13C UBT) in humans — direct gut antimicrobial/health effect.
- Effects of lactoferrin and lactoperoxidase-containing food on the oral microbiota of older individuals
PubMed ID: 28881387
LF+lactoperoxidase tablets reduced gram‑negative oral bacteria and altered oral microbiota diversity correlated with improved oral health — strong microbial community effect in the mouth.
- Iron metabolism in infants: influence of bovine lactoferrin from iron-fortified formula
PubMed ID: 25592008
Lactoferrin‑fortified iron formula increased Hb/ferritin/TBIC and reduced iron deficiency/anemia in infants; improved gut‑related iron nutrition outcomes.
- Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial
PubMed ID: 26602290
Lactoferrin‑fortified formula significantly reduced diarrhea incidence in weaned infants over 3 months versus control.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
In pediatric IBD with iron‑deficiency anemia, lactoferrin improved hematology and lowered inflammatory markers—direct gut‑disease population benefit.
- Use of bovine lactoferrin for Helicobacter pylori eradication
PubMed ID: 14620619
Bovine lactoferrin adjunct markedly improved H. pylori eradication—direct gut-related clinical benefit.
- Use of lactoferrin for Helicobacter pylori eradication. Preliminary results
PubMed ID: 12702979
Preliminary study showed high H. pylori cure rates when lactoferrin was added to triple therapy (supports gut benefit).
- Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study
PubMed ID: 16611285
Large multicenter trial: lactoferrin increased H. pylori eradication—clinically meaningful gut effect.
- Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics
PubMed ID: 17313499
Lactoferrin plus probiotics increased H. pylori cure rates and reduced side effects (gut health support).
- Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea
PubMed ID: 17255841
ORS with recombinant lactoferrin + lysozyme shortened diarrhea in young children (direct gut clinical benefit).
- Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial
PubMed ID: 24709463
Large VLBW infant RCT showed reduced NEC and death-or-NEC with BLF ± probiotic — strong evidence of gut-protective effects in neonates.
- Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children
PubMed ID: 18462105
In Peruvian toddlers, bovine lactoferrin significantly reduced Giardia carriage and shortened duration of carriage — strong gut‑pathogen benefit.
Illness recovery (14)
- Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial
PubMed ID: 39565449
bLF significantly shortened time to full enteral feeding in preterm infants — a clear recovery‑related endpoint.
- Efficacy of Bovine Lactoferrin Supplementation in Preventing Late-onset Sepsis in low Birth Weight Neonates: A Randomized Placebo-Controlled Clinical Trial
PubMed ID: 26224129
Randomized trial in low-birth-weight neonates showed reduced culture-proven late-onset sepsis and eliminated sepsis-attributable deaths in the LF arm, consistent with improved clinical recovery/avoidance of deterioration.
- Effects of lactoferrin on infectious diseases in Japanese summer: A randomized, double-blinded, placebo-controlled trial
PubMed ID: 32151562
Healthy adults taking LF had ~1 day shorter duration of infectious illnesses (faster symptom resolution).
- A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis
PubMed ID: 23425819
Enteral talactoferrin in severe sepsis was associated with markedly lower 28‑day and 6‑month mortality, implying improved recovery in a severe illness setting (phase II).
- Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study
PubMed ID: 17188087
Topical recombinant lactoferrin showed a trend toward improved diabetic foot‑ulcer healing (wound recovery) in a small human trial.
- Supporting respiratory epithelia and lowering inflammation to effectively treat common cold symptoms: A randomized controlled trial
PubMed ID: 39602479
Topical throat spray containing LF+lysozyme+aloe markedly reduced sore throat pain and overall cold symptoms rapidly (faster symptom relief).
- Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea
PubMed ID: 17255841
Lactoferrin-containing ORS shortened diarrhea and increased recovery at 48 h in young children (faster clinical recovery).
- Preventing Sepsis in Preterm Infants with Bovine Lactoferrin: A Randomized Trial Exploring Immune and Antioxidant Effects
PubMed ID: 41097231
Enteral bovine lactoferrin reduced late‑onset sepsis incidence in very preterm infants, implying quicker clinical recovery/less morbidity.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
In IBD children with IDA, lactoferrin produced faster hematologic improvement vs ferrous sulfate.
- PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trial
PubMed ID: 25340801
Lactoferrin‑derived peptide (PXL01) improved distal joint motion and functional recovery after tendon repair versus placebo.
- THE EFFECT OF ENTERAL LACTOFERRIN SUPPLEMENTATION IN PREVENTION OF MORBIDITY ASSOCIATED WITH IMMATURE DIGESTIVE TRACT IN PREMATURE INFANTS: PROSPECTIVE COHORT STUDY
PubMed ID: 35271478
Enteral lactoferrin shortened time to full enteral feeds and reduced hospital stay in the smallest preterm infants (faster clinical recovery).
- Oral colostrum priming shortens hospitalization without changing the immunomicrobial milieu
PubMed ID: 27684425
Oropharyngeal colostrum priming in very preterm infants shortened hospital stay by ~16 days — clinically meaningful faster recovery.
- Oropharyngeal colostrum administration in extremely premature infants: an RCT
PubMed ID: 25624376
Tiny oropharyngeal colostrum doses raised immune markers and reduced clinical sepsis in preterms — supports faster/safer recovery from infection risk.
- Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial
PubMed ID: 24709463
Large VLBW trial reduced NEC and death-or-NEC (especially with probiotic), outcomes that relate to recovery and survival in neonates.
Digestive support (12)
- Effects of Lactoferrin on Prevention of Acute Gastrointestinal Symptoms in Winter: A Randomized, Double-Blinded, Placebo-Controlled Trial for Staff of Kindergartens and Nursery Schools in Japan
PubMed ID: 33371454
Reduced prevalence/duration of acute GI symptoms and diarrhea in childcare workers taking lactoferrin (meaningful clinical reduction).
- Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 30829679
Malawian toddlers given LF+lysozyme had improved gut-barrier biomarkers and much lower hospitalizations/acute malnutrition (improves GI resilience).
- Antibiotic treatment to prevent postextraction complications: a monocentric, randomized clinical trial. Preliminary outcomes
PubMed ID: 28569454
Randomized trial where a probiotic product containing lactoferrin markedly reduced antibiotic-associated GI side effects after tooth extraction (attribution to LF limited but clinically relevant).
- Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea
PubMed ID: 17255841
Recombinant lactoferrin + lysozyme in ORS significantly shortened diarrhea duration and improved recovery in children.
- Lactoferrin versus iron hydroxide polymaltose complex for the treatment of iron deficiency anemia in children with cerebral palsy: a randomized controlled trial
PubMed ID: 34101010
Children had less constipation and better Hb/ferritin with lactoferrin vs iron complex, indicating reduced GI adverse effects.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
In pediatric IBD with IDA, lactoferrin caused far fewer GI side effects vs ferrous sulfate.
- Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial
PubMed ID: 34102559
Bovine LF in weaned infants reduced diarrhea morbidity (directly reduces digestive symptoms).
- Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study
PubMed ID: 16369731
Oral bovine LF substantially reduced H. pylori colonization (may relieve H. pylori-related dyspepsia).
- Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study
PubMed ID: 19639462
Pregnant women had similar iron correction but significantly fewer GI side effects with bovine lactoferrin vs ferrous sulfate.
- Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial
PubMed ID: 39565449
Pilot RCT in preterm infants showed shorter time to full feeds (improved feeding tolerance) with oral bLF — directly relevant to digestive comfort.
- Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy: a randomized clinical trial
PubMed ID: 26037728
Large RCT in pregnancy: greater Hb increases with markedly better tolerability (fewer GI adverse events) vs ferrous sulfate.
- The Preventive Effect of Lactoferrin-Containing Yogurt on Gastroenteritis in Nursery School Children-Intervention Study for 15 Weeks
PubMed ID: 32272777
Nursery children consuming LF yogurt had fewer vomiting-related absences and fewer sick days.
Nutrient uptake (11)
- Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial
PubMed ID: 39565449
Faster achievement of full enteral feeds and lower intestinal permeability in preterm infants suggests improved nutrient uptake/handling with oral bLF.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
In IBD children with IDA, lactoferrin raised hemoglobin and ferritin more than ferrous sulfate, showing superior iron outcomes.
- Dose Effect of Bovine Lactoferrin Fortification on Iron Metabolism of Anemic Infants
PubMed ID: 32115450
In anemic infants, higher bovine lactoferrin in formula improved hemoglobin after 3 months, supporting improved iron status/handling.
- Iron metabolism in infants: influence of bovine lactoferrin from iron-fortified formula
PubMed ID: 25592008
Infant RCT: lactoferrin‑fortified iron formula raised Hb, SF and TBIC and reduced anemia/iron deficiency vs control.
- Effects of a Novel High-Quality Protein Infant Formula on Energetic Efficiency and Tolerance: A Randomized Trial
PubMed ID: 35666855
Formula containing lactoferrin produced similar growth with lower intake and higher energetic efficiency, indicating enhanced nutrient utilization.
- Lactoferrin versus iron hydroxide polymaltose complex for the treatment of iron deficiency anemia in children with cerebral palsy: a randomized controlled trial
PubMed ID: 34101010
Children with cerebral palsy: lactoferrin produced greater Hb and ferritin improvements vs iron hydroxide polymaltose.
- Lactoferrin plus health education versus total dose infusion (TDI) of low-molecular weight (LMW) iron dextran for treating iron deficiency anemia (IDA) in pregnancy: a randomized controlled trial
PubMed ID: 29338568
Pregnant women: lactoferrin sachets + education gave similar short‑term Hb improvement to total‑dose IV iron (mixed iron index results).
- Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy: a randomized clinical trial
PubMed ID: 26037728
Well‑powered pregnancy RCT: lactoferrin produced significantly greater Hb increases than ferrous sulfate over 8 weeks.
- Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study
PubMed ID: 20647390
Anemic chemo patients on rHuEPO: oral lactoferrin produced Hb responses similar to IV iron (adjunctive effect).
- Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study
PubMed ID: 19639462
Pregnant women: bovine lactoferrin corrected iron deficiency comparably to ferrous sulfate with fewer side effects (effective absorption/utilization).
- Lactoferrin: A Promising New Player in Treatment of Iron Deficiency Anemia in Patients on Regular Hemodialysis: A Randomized Controlled Trial
PubMed ID: 38231718
Large RCT in hemodialysis patients: oral bovine lactoferrin dramatically lowered hepcidin and raised hemoglobin and transferrin saturation vs oral iron.
Inflammation (11)
- Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells
PubMed ID: 24839144
LF-treated preterm infants showed increased T-regulatory responses alongside reduced sepsis, suggesting an immunoregulatory / anti-inflammatory effect.
- Vaginal lactoferrin in asymptomatic patients at low risk for pre-term labour for shortened cervix: cervical length and interleukin-6 changes
PubMed ID: 23445135
Vaginal lactoferrin reduced cervical IL‑6 and increased cervical length in pregnant women with borderline short cervix, indicating localized anti‑inflammatory effects.
- Preventing Sepsis in Preterm Infants with Bovine Lactoferrin: A Randomized Trial Exploring Immune and Antioxidant Effects
PubMed ID: 41097231
bLf preserved antioxidant capacity and altered cytokine trajectories in VLBW infants, consistent with inflammation modulation.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
In pediatric IBD, lactoferrin lowered IL‑6 and hepcidin (clear anti‑inflammatory/immunomodulatory signal).
- Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
PubMed ID: 27872513
Vaginal lactoferrin decreased PGE2 and active MMP‑9 and altered MMP‑2/TIMP patterns in amniotic fluid, consistent with anti‑inflammatory and remodeling effects.
- Vaginal lactoferrin administration before genetic amniocentesis decreases amniotic interleukin-6 levels
PubMed ID: 24642648
Vaginal lactoferrin given 4 h before amniocentesis significantly lowered amniotic IL‑6 versus controls.
- Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes
PubMed ID: 32065880
WPI product containing standardized lactoferrin reduced inflammatory markers (hsCRP, IL‑6, TNF‑α) though LF was a small component.
- Oral lactoferrin as a treatment of pediatrics' anemia resulted from chronic kidney diseases: a randomized controlled trial
PubMed ID: 39910177
In children with CKD, oral lactoferrin improved Hb and markedly reduced inflammatory biomarkers IL‑6 and GDF‑15.
- Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine
PubMed ID: 24867408
3 g/day bLF increased polyp-associated immune cells and inhibited polyp growth in a subgroup — evidence of tissue-level immune modulation and anti‑inflammatory effects.
- Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women
PubMed ID: 20473630
Ribonuclease‑enriched LF supplement markedly reduced IL‑6 and TNF‑α and raised IL‑10 in postmenopausal women (direct anti‑inflammatory evidence).
- A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial
PubMed ID: 38732615
Multi‑ingredient supplement with LF reduced CRP and TNF‑α and zonulin (anti‑inflammatory and gut permeability effects) in older adults.
Respiratory comfort (6)
- Dose effect of bovine lactoferrin fortification on diarrhea and respiratory tract infections in weaned infants with anemia: A randomized, controlled trial
PubMed ID: 34102559
Bovine LF reduced respiratory‑related illness and wheezing in anemic weaned infants (direct respiratory outcome).
- Randomized Controlled Trial of Bovine Lactoferrin for Prevention of Sepsis and Neurodevelopment Impairment in Infants Weighing Less Than 2000 Grams
PubMed ID: 32037149
Fewer rehospitalizations for bronchiolitis in low-birth-weight infants receiving LF (clinically meaningful respiratory benefit).
- Improved Neurodevelopmental Outcomes Associated with Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula: A Randomized, Controlled Trial
PubMed ID: 31668885
Infants on MFGM+LF formula had fewer respiratory adverse events vs control (suggests improved respiratory health).
- Supporting respiratory epithelia and lowering inflammation to effectively treat common cold symptoms: A randomized controlled trial
PubMed ID: 39602479
Mucosal spray containing LF (plus lysozyme/aloe) rapidly reduced sore throat and overall cold symptoms—direct respiratory benefit.
- Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial
PubMed ID: 26602290
Weaned infants fed lactoferrin‑fortified formula experienced fewer respiratory symptoms/RTIs over 3 months versus control.
- A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants
PubMed ID: 17255839
Infant formula with bovine lactoferrin was associated with fewer lower respiratory tract events/wheezing in a randomized infant trial.
Oral health (7)
- The effect of enzyme and protein containing toothpaste on gingival condition: a randomised controlled study
PubMed ID: 41184910
Toothpaste containing lactoferrin and enzymes produced large, significant improvements in gingival inflammation and plaque vs control over 26 weeks.
- Effects of lactoferrin and lactoperoxidase-containing food on the oral microbiota of older individuals
PubMed ID: 28881387
Eight‑week RCT of tablets containing bovine LF + lactoperoxidase significantly reduced gram‑negative oral bacteria and improved oral malodor/plaque — direct, high-quality evidence.
- Efficacy of natural enzymes mouthwash: a randomised controlled trial
PubMed ID: 38639763
Natural‑enzyme mouthwash containing lactoferrin improved xerostomia scores and salivary flow versus comparator — clinically meaningful oral benefit though multi‑ingredient.
- Effect of tablets containing lactoferrin and lactoperoxidase on gingival health in adults: A randomized, double-blind, placebo-controlled clinical trial
PubMed ID: 31292969
Randomized double-blind trial: bovine LF + lactoperoxidase tablets significantly improved gingival inflammation, plaque, and oral-health quality of life.
- A randomized, double-blind, crossover, placebo-controlled clinical trial to assess effects of the single ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose oxidase on oral malodor
PubMed ID: 27001471
Randomized crossover trial: single LF-containing lozenge produced rapid, large reductions in volatile sulfur compounds (oral malodor) — strong, direct oral-health benefit.
- Effects of lactoferrin and lactoperoxidase-containing food on the oral hygiene status of older individuals: A randomized, double blinded, placebo-controlled clinical trial
PubMed ID: 27150460
Randomized placebo-controlled trial in elderly subjects: LF+lactoperoxidase lozenges reduced total oral bacterial load and key periodontal pathogens over 8 weeks (good evidence for oral-health benefit).
- Effects of Lactoferrin on Oral and Throat Conditions under Low Humidity Environments: A Randomized, Double-Blind, and Placebo-Controlled Crossover Trial
PubMed ID: 37764816
Single oral lactoferrin dose reduced mouth and throat dryness in healthy adults exposed to low humidity (subjective symptom improvement).
Energy & Fatigue (4)
- Lactoferrin: A Promising New Player in Treatment of Iron Deficiency Anemia in Patients on Regular Hemodialysis: A Randomized Controlled Trial
PubMed ID: 38231718
Large Hb increases in hemodialysis patients with lactoferrin (vs oral iron) are likely to translate into improved energy/fatigue.
- Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial
PubMed ID: 35681097
Lactoferrin improved hemoglobin substantially in IBD‑associated IDA, which would be expected to increase energy.
- Iron metabolism in infants: influence of bovine lactoferrin from iron-fortified formula
PubMed ID: 25592008
Infants on lactoferrin‑fortified formula had higher Hb and lower anemia prevalence, suggesting better energy/physiologic function.
- Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy: a randomized clinical trial
PubMed ID: 26037728
Pregnant women showed clinically meaningful Hb increases with lactoferrin, which can improve energy levels.
Acne (3)
- A randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of lactoferrin with vitamin E and zinc as an oral therapy for mild to moderate acne vulgaris
PubMed ID: 28369875
3‑month randomized trial of lactoferrin+vitamin E+zinc reduced total and inflammatory acne lesions, but effect cannot be ascribed to lactoferrin alone.
- Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study
PubMed ID: 10948819
Oral bovine lactoferrin trial showed symptomatic improvement in a subgroup with moderate tinea pedis (direct supplementation → dermatologic symptom benefit).
- Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris
PubMed ID: 20692602
Randomized trial: daily lactoferrin‑enriched fermented milk reduced inflammatory acne lesions, total lesions and sebum (direct clinical benefit).
Healthy aging (3)
- A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial
PubMed ID: 38732615
Multi‑ingredient supplement including LF improved muscle mass/strength and lowered inflammatory markers in older adults with sarcopenia.
- Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine
PubMed ID: 24867408
One-year 3 g/day bLF inhibited colorectal polyp growth (immune/tissue effects relevant to cancer prevention and aging-related GI pathology) in ≤63-year subgroup.
- Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women
PubMed ID: 19172341
Ribonuclease‑enriched lactoferrin supplement reduced bone resorption and increased formation markers in postmenopausal women.
Weight management (2)
- Effects of a Novel High-Quality Protein Infant Formula on Energetic Efficiency and Tolerance: A Randomized Trial
PubMed ID: 35666855
Infant formula with lactoferrin supported normal growth with less formula/protein intake and higher growth efficiency—relevant to healthy weight/efficiency.
- Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 30829679
LF+lysozyme dramatically reduced acute malnutrition/hospitalization in at-risk toddlers (supports healthier weight/nutrition outcomes).
Mood balance (1)
- Effects of a Bovine Lactoferrin Formulation from Cow's Milk on Menstrual Distress in Volunteers: A Randomized, Crossover Study
PubMed ID: 27258249
Iron‑lactoferrin reduced autonomic distress scores and shifted HRV toward parasympathetic dominance during menses, indicating mood/affect benefits in that context.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Lactoferrin
Search all166 products whose verified label declares Lactoferrin — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.